Skip to main content

Advertisement

SpringerLink
Log in

Zoledronic acid concurrent with either high- or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: a phase IV randomized clinical study

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Introduction

In this prospective study, the efficacy and safety of radiotherapy combined with zoledronic acid was evaluated.

Materials and methods

Breast cancer patients with painful bone metastases were randomized to either high- or reduced-dose radiotherapy. All patients received zoledronic acid (4 mg) every 28 days from the beginning of radiotherapy. Analgesic and pain scores in addition to visual analog score (VAS) for treatment satisfaction and whole-body bone scintigraphy were evaluated.

Results and conclusion

No significant differences could be found in analgesic or pain scores and bone scintigraphy results between the groups. Our results suggest that reduced-dose radiotherapy produces similar response rates and response durations when used concomitantly with zoledronic acid.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Domchek SM, Younger J, Finkelstein DM, Seiden MW (2000) Predictors of skeletal complications in patients with metastatic breast carcinoma. Cancer 89:363–368. doi:10.1002/1097-0142(20000715)89:2<363::AID-CNCR22>3.0.CO;2-3

    Article  CAS  PubMed  Google Scholar 

  2. Lipton A (2005) Management of bone metastases in breast cancer. Curr Treat Options Oncol 6:161–171. doi:10.1007/s11864-005-0023-0

    Article  PubMed  Google Scholar 

  3. Coleman RE (2001) Metastatic bone disease: clinical features, pathophsiology and treatment strategies. Cancer Treat Rev 27:165–176. doi:10.1053/ctrv.2000.0210

    Article  CAS  PubMed  Google Scholar 

  4. Coleman RE, Rubens RD (1987) The clinical course of bone metastases from breast cancer. Br J Cancer 55:61–66

    CAS  PubMed  Google Scholar 

  5. Bates T (1992) A review of local radiotherapy in the treatment of bone metastases and cord compression. Int J Radiat Oncol Biol Phys 23:217–221

    CAS  PubMed  Google Scholar 

  6. Maher EJ (1992) The use of palliative radiotherapy in the management of breast cancer. Eur J Cancer 28:706–710. doi:10.1016/S0959-8049(05)80131-5

    Article  CAS  PubMed  Google Scholar 

  7. Fleisch H (2002) Development of bisphophonates. Breast Cancer Res 4:30–34. doi:10.1186/bcr414

    Article  CAS  PubMed  Google Scholar 

  8. Gnant M, Mlineritsch B, Schippinger W et al (2008) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9:840–849. doi:10.1016/S1470-2045(08)70204-3

    Article  CAS  PubMed  Google Scholar 

  9. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S, American Society of Clinical Oncology (2003) 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042–4057. doi:10.1200/JCO.2003.08.017

    Article  CAS  PubMed  Google Scholar 

  10. Price P, Hoskin PJ, Easton D, Austin D, Palmer SG, Easton D, Austin D, Palmer SG, Yarnold JR (1986) Prospective randomized trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol 6:247–255. doi:10.1016/S0167-8140(86)80191-8

    Article  CAS  PubMed  Google Scholar 

  11. Tong D, Gillick L, Hendrickson FR (1982) The palliation of symptomatic osseous metastases. Final results of the study by the Radiation Therapy Oncology Group. Cancer 50:893–899. doi:10.1002/1097-0142(19820901)50:5<893::AID-CNCR2820500515>3.0.CO;2-Y

    Article  CAS  PubMed  Google Scholar 

  12. Madsen EL (1983) Painful bone metastases: efficacy of radiotherapy assessed by the patients: a randomized trial comparing 4 Gy × 6 versus 10 Gy × 2. Int J Radiat Oncol Biol Phys 9:1775–1779

    CAS  PubMed  Google Scholar 

  13. Hartsell WF, Scott CB, Bruner DW, Scarantino CW, Ivker RA, Roach M, Suh JH, Demas WF, Movsas B, Petersen IA, Konski AA, Cleeland CS, Janjan NA, DeSilvio M (2005) Randomized trial of short- versus long- course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 11:798–804

    Google Scholar 

  14. Wu JS, Wong R, Johnston M, Bezjak A, Whelan T (2003) Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 55:594–605. doi:10.1016/S0360-3016(02)04147-0

    PubMed  Google Scholar 

  15. van den Hout WB, van der Linden YM, Steenland E, Wiggenraad RG, Kievit J, de Haes H, Leer JW (2003) Single- versus multipl- fraction radiotherapy in patients with painful bone metastases: cost-Utility analysis based on a randomized trial. J Natl Cancer Inst 95:222–229

    Article  PubMed  Google Scholar 

  16. Sze WM, Shelley MD, Held I, Wilt TJ, Mason MD (2003) Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy- A systematic rewiev of randomized trials. Clin Oncol 15:345–352. doi:10.1016/S0936-6555(03)00113-4

    Article  CAS  Google Scholar 

  17. Crellin AM, Marks A, Maher EJ (1989) Why don’t British radiotherapists give single fractions of radiotherapy for bone metastases. Clin Oncol 1:63–66. doi:10.1016/S0936-6555(89)80036-6

    Article  CAS  Google Scholar 

  18. Flanagan AM, Chambers TJ (1991) Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone. Calcif Tissue Int 49:407–415. doi:10.1007/BF02555852

    Article  CAS  PubMed  Google Scholar 

  19. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88(Suppl):2961–2978. doi:10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L

    Article  CAS  PubMed  Google Scholar 

  20. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ (2001) Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorptio in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296:235–242

    CAS  PubMed  Google Scholar 

  21. Alakangas A, Selander K, Mulari M, Halleen J, Lehenkari P, Mönkkönen J, Salo J, Väänänen K (2002) Alendronate disturbs vesicular trafficking in osteoclasts. Calcif Tissue Int 70:40–47. doi:10.1007/s002230010047

    Article  CAS  PubMed  Google Scholar 

  22. Fisher JE, Rodan GA, Reszka AA (2000) In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology 141:4793–4796. doi:10.1210/en.141.12.4793

    Article  CAS  PubMed  Google Scholar 

  23. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337–342. doi:10.1038/nature01658

    Article  CAS  PubMed  Google Scholar 

  24. Pavlakis N, Schmidt RL, Stockler M (2005) Bisphosphonates for breast cancer. Cochrane Database Syst Rev 3:CD003474

    Google Scholar 

  25. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen BL, Seaman JJ (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98:1735–1744. doi:10.1002/cncr.11701

    Article  CAS  PubMed  Google Scholar 

  26. Rosen LS, Gordon DH, Dugan W Jr, Major P, Eisenberg PD, Provencher L, Kaminski M, Simeone J, Seaman J, Chen BL, Coleman RE (2004) Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100:36–43. doi:10.1002/cncr.11892

    Article  CAS  PubMed  Google Scholar 

  27. Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe T, Goessl C, Ohashi Y, Takashima S (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a Randomized, Placebo-Controlled Trial. J Clin Oncol 23:3314–3321. doi:10.1200/JCO.2005.05.116

    Article  CAS  PubMed  Google Scholar 

  28. Coleman RE, Rosen LS, Gordon D, Major P, Kaminski M, Apffelstaedt J, Howell A, Chen B-L, Seaman JJ (2002) Zoledronic acid (4 mg) significantly reduces the relative risk of developing a skeletal–related event compared with pamidronate (90 mg) in patients with breast cancer and bone metastasis. Breast Cancer Res Treat 76(suppl.):355

    Google Scholar 

  29. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW (2000) Bisphophonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82:1459–1468

    CAS  PubMed  Google Scholar 

  30. Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ (2001) Osteoprotegrin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastases. Cancer Res 61:4432–4436

    CAS  PubMed  Google Scholar 

  31. van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Löwik C, Papapoulos S (1996) Biphophonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 98:698–705. doi:10.1172/JCI118841

    Article  PubMed  Google Scholar 

  32. Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD, Clezardin P (1997) Biphophonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 57:3890–3894

    CAS  PubMed  Google Scholar 

  33. Vogt U, Bielawski KP, Bosse U, Schlotter CM (2004) Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid. Oncol Rep 12:1109–1114

    CAS  PubMed  Google Scholar 

  34. Jagdev SP, Coleman RE, Shipman CM, Rostami-H A, Croucher PI (2001) The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 84:1126–1134. doi:10.1054/bjoc.2001.1727

    Article  CAS  PubMed  Google Scholar 

  35. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE, Holen I (2005) Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 113:364–371. doi:10.1002/ijc.20602

    Article  CAS  PubMed  Google Scholar 

  36. Magnetto S, Boissier S, Delmas PD, Clezardin P (1999) Additive antitumor activities of taxoids in combination with the biphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer 83:263–269. doi:10.1002/(SICI)1097-0215(19991008)83:2<263::AID-IJC19>3.0.CO;2-T

    Article  CAS  PubMed  Google Scholar 

  37. Ural AU, Avcu F, Candir M, Guden M, Ozcan MA (2006) In vitro synergistic effects of zoledronic acid and radiation on breast cancer cells. Breast Cancer Res 8:R52. doi:10.1186/bcr1543

    Article  PubMed  CAS  Google Scholar 

  38. Arrington SA, Damron TA, Mann KA, Allen MJ (2008) Concurrent administration of zoledronic acid and irradiation leads to improved bone density, biomechanical strength, and microarchitecture in a mouse model of tumor-induced osteolysis. J Surg Oncol 97:284–290. doi:10.1002/jso.20949

    Article  CAS  PubMed  Google Scholar 

  39. Blitzer PH (1985) Reanalysis of the RTOG study of the palliation of symptomatic osseous metastasis. Cancer 55:1468–1472. doi:10.1002/1097-0142(19850401)55:7<1468::AID-CNCR2820550708>3.0.CO;2-M

    Article  CAS  PubMed  Google Scholar 

Download references

Declaration of interest

Any actual or potential conflicts of interest do not exist.

Author information

Author notes

  1. Kayıhan Engin

    Present address: Department of Radiation Oncology, Anadolu Sağlık Merkezi, İstanbul, Turkey

Authors and Affiliations

  1. Department of Radiation Oncology, Hacettepe University, Ankara, 06100, Turkey

    Lale Atahan, Ferah Yıldız & Mustafa Cengiz

  2. Department of Radiation Oncology, Erciyes University, Kayseri, Turkey

    Bunyamin Kaplan, Metin Özkan & Mete Gündoğ

  3. Department of Radiation Oncology, Ankara Education and Investigation Hospital of Ministry of Health, Ankara, Turkey

    Gozde Yazici

  4. Department of Radiation Oncology, Ege University, İzmir, Turkey

    Ayfer Haydaroğlu

  5. Department of Radiation Oncology, Akdeniz University, Antalya, Turkey

    Aylin F. Korcum

  6. Department of Radiation Oncology, Marmara University, Istanbul, Turkey

    Meriç Şengöz

  7. İstanbul University, İstanbul, Turkey

    Maktav Dinçer

  8. Department of Radiation Oncology, Gazi University, Ankara, Turkey

    Müge Akmansu

  9. Department of Radiation Oncology, Uludağ University, Bursa, Turkey

    Kayıhan Engin

  10. Department of Preventive Oncology, Hacettepe University, Ankara, 06100, Turkey

    Mutlu Hayran

Authors
  1. Lale Atahan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ferah Yıldız
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mustafa Cengiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bunyamin Kaplan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Metin Özkan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gozde Yazici
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mete Gündoğ
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ayfer Haydaroğlu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Aylin F. Korcum
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Meriç Şengöz
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Maktav Dinçer
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Müge Akmansu
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Kayıhan Engin
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Mutlu Hayran
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ferah Yıldız.

Additional information

Lale Atahan, Deceased

Rights and permissions

Reprints and permissions

About this article

Cite this article

Atahan, L., Yıldız, F., Cengiz, M. et al. Zoledronic acid concurrent with either high- or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: a phase IV randomized clinical study. Support Care Cancer 18, 691–698 (2010). https://doi.org/10.1007/s00520-009-0663-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-009-0663-x

Keywords

Search

Navigation